Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||rectum cancer||not applicable||Nelfinavir + Radiotherapy||Phase I||Actionable||In a Phase I trial, the combination of Nelfinavir and radiotherapy resulted in median tumor cell density reduction from 24.3% at baseline to 9.2%, and tumor regression in 56% (5/9) of rectal cancer patients (PMID: 26861457).||26861457|